Portal de Periódicos da CAPES

A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease

1996; American Psychiatric Association Publishing; Volume: 8; Issue: 3 Linguagem: Inglês

10.1176/jnp.8.3.270

1545-7222

Gustavo Petracca, Alejandra Tesón, Erán Chemerinski, R. Leiguarda, Sergio Starkstein,

Neurological Disorders and Treatments

Twenty-one depressed patients with probable Alzheimer's disease (AD) were randomized to receive a 6-week treatment with clomipramine or placebo in a study with a double-blind crossover design. Main outcome measures were Hamilton Depression, Mini-Mental State (MMSE), and Functional Independence Measure (FIM) scores. Mood improved significantly on both clomipramine and placebo, but clomipramine was significantly more effective than placebo during the first 6-week treatment period. Patients started on clomipramine maintained improvement during the washout and placebo periods, whereas patients started on placebo worsened during the washout period. However, patients on clomipramine showed significantly lower MMSE scores overall than patients on placebo. No significant drug effects were found on FIM scores. Clomipramine proved to be a useful treatment of depression in patients with probable AD.